1877 — Shanghai Junshi Biosciences Co Share Price
Last trade - 00:00- HK$9.11bn
- HK$7.14bn
- CNY1.50bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.18 | ||
| Price to Tang. Book | 1.27 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 5.6 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -27.6% | ||
| Return on Equity | -27.45% | ||
| Operating Margin | -163.55% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 775.09 | 1,594.9 | 4,024.84 | 1,453.49 | 1,502.55 | 2,126.09 | 3,057.39 | 248.39% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Shanghai Junshi Biosciences Co Ltd is a China-based company mainly engaged in innovation-driven biopharmaceutical business. The Company's main businesses are the discovery, clinical research and development of innovative drugs. The Company's main products include teriprizumab injection, Etesevimab, adalimumab injection and other drugs, which are used to treat malignant tumors, autoimmune system diseases, chronic metabolic diseases, nervous system diseases and infectious diseases . The Company is also engaged in the clinical research and development of recombinant humanized anti-PCSK9 monoclonal antibody injection and other drugs. The Company provides its products for domestic and overseas markets.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 27th, 2012
- Public Since
- December 24th, 2018
- No. of Shareholders
- 33,007
- No. of Employees
- 2,568
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 985,689,871
- Address
- 16F, Building 7, No. 6, Lane 100, SHANGHAI, 201203
- Web
- https://www.junshipharma.com/
- Phone
- +86 2161058800
- Contact
- Yingge Chen
- Auditors
- Rongcheng Accounting Firm
Upcoming Events for 1877
Similar to 1877
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
Asymchem Laboratories Tianjin Co
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 19:12 UTC, shares in Shanghai Junshi Biosciences Co are trading at HK$9.24. This share price information is delayed by 15 minutes.
Shares in Shanghai Junshi Biosciences Co last closed at HK$9.24 and the price had moved by -69.2% over the past 365 days. In terms of relative price strength the Shanghai Junshi Biosciences Co share price has underperformed the FTSE Developed Asia Pacific Index by -67.85% over the past year.
The overall consensus recommendation for Shanghai Junshi Biosciences Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Shanghai Junshi Biosciences Co does not currently pay a dividend.
Shanghai Junshi Biosciences Co does not currently pay a dividend.
Shanghai Junshi Biosciences Co does not currently pay a dividend.
To buy shares in Shanghai Junshi Biosciences Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$9.24, shares in Shanghai Junshi Biosciences Co had a market capitalisation of HK$9.11bn.
Here are the trading details for Shanghai Junshi Biosciences Co:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 1877
Based on an overall assessment of its quality, value and momentum Shanghai Junshi Biosciences Co is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Shanghai Junshi Biosciences Co is HK$38.39. That is 315.44% above the last closing price of HK$9.24.
Analysts covering Shanghai Junshi Biosciences Co currently have a consensus Earnings Per Share (EPS) forecast of -CNY1.45 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Shanghai Junshi Biosciences Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -52.78%.
As of the last closing price of HK$9.24, shares in Shanghai Junshi Biosciences Co were trading -48.58% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Shanghai Junshi Biosciences Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$9.24.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Shanghai Junshi Biosciences Co's management team is headed by:
- Cong Li - CCE
- Ning Li - EDR
- Jun Xiong - EDR
- Yi Tang - NED
- Xiaoyuan Feng - NID
- Zhi Qian - NID
- Chun Zhang - NID